PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.\', \'Janssen Research and Development, LLC, Spring House, Pennsylvania.\', \'Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine and the Cincinnati Children\'s Hospital Medical Center, Cincinnati, Ohio.\', \'Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.\', \'Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Children\'s Healthcare of Atlanta, Atlanta, Georgia.\', \'Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio.\', \'F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: dermot.mcgovern@cshs.org.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0016-5085(20)35331-210.1053/j.gastro.2020.10.041
?:doi
?:hasPublicationType
?:journal
  • Gastroenterology
is ?:pmid of
?:pmid
?:pmid
  • 33160965
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.958
?:rankingScore_hIndex
  • 357
is ?:relation_isRelatedTo_publication of
?:title
  • Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all